

AD \_\_\_\_\_

Award Number: W81XWH-08-1-0532

TITLE: Structure and Function of the Splice Variants of TMPRSS2-ERG, a Prevalent Genomic Alteration in Prostate Cancer

PRINCIPAL INVESTIGATOR: Dr. Shiv Srivastava

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation  
Rockville, MD 20652

REPORT DATE: September 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                  |                          |                                      | Form Approved<br>OMB No. 0704-0188                       |                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------|--------------------------------------|----------------------------------------------------------|--------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>                                                                                                                                                                                                                                                                                                                                                   |                  |                          |                                      |                                                          |                                            |
| 1. REPORT DATE (DD-MM-YYYY)<br>01-09-2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                  | 2. REPORT TYPE<br>Annual |                                      | 3. DATES COVERED (From - To)<br>15 Aug 2010 - 14Aug 2011 |                                            |
| 4. TITLE AND SUBTITLE<br>Structure and Function of the Splice Variants of TMPRSS2-ERG, a Prevalent Genomic Alteration in Prostate Cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                  |                          |                                      | 5a. CONTRACT NUMBER                                      |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          |                                      | 5b. GRANT NUMBER<br>W81XWH-08-1-0532                     |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          |                                      | 5c. PROGRAM ELEMENT NUMBER                               |                                            |
| 6. AUTHOR(S)<br><br>Dr. Shiv Srivastava<br><br>E-Mail: ssrivastava@cpdr.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                  |                          |                                      | 5d. PROJECT NUMBER                                       |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          |                                      | 5e. TASK NUMBER                                          |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          |                                      | 5f. WORK UNIT NUMBER                                     |                                            |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Henry M. Jackson Foundation<br>Rockville, MD 20652                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                  |                          |                                      | 8. PERFORMING ORGANIZATION REPORT NUMBER                 |                                            |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                  |                          |                                      | 10. SPONSOR/MONITOR'S ACRONYM(S)                         |                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          |                                      | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)                   |                                            |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                  |                          |                                      |                                                          |                                            |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                  |                          |                                      |                                                          |                                            |
| 14. ABSTRACT<br>The most common early genetic defect in prostate cancer (CaP) is the TMPRSS2-ERG gene fusion that results in the expression of the ERG protooncogene. In the context of rearranged genome ERG is transcribed under the control of the androgen inducible TMPRSS2 promoter producing cancer-associated splice variants of ERG. Although, much has been learned in recent years about gene fusions in prostate cancer, the function of TMPRSS2-ERG splice variants is not well understood. However, this information is critical in order to understand ERG functions and its therapeutic targeting in CaP. We have identified two major classes of full-length transcripts of ERG, Type I and Type II splice variants, by screening a cDNA library of TMPRSS2-ERG fusion harboring human prostate tumors. Type I over Type II increased ratios correlated with poor prognostic and clinico-pathologic features of CaP. Moreover, we have found the dominant presence of Type II form in prostate cancer cells. Functional interaction between Type II and Type I splice variants in prostate tumor cells is currently under investigation. Expression of ERG splice variants in human CaP, and the relative ratio of splice variants may provide new strategy in prognosing prostate cancer. |                  |                          |                                      |                                                          |                                            |
| 15. SUBJECT TERMS<br>Prostate cancer, ERG oncogene, Splice variants, TMPRSS2-ERG8, TMPRSS2-ERG3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          |                                      |                                                          |                                            |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                  |                          | 17. LIMITATION OF ABSTRACT<br><br>UU | 18. NUMBER OF PAGES<br><br>29                            | 19a. NAME OF RESPONSIBLE PERSON<br>USAMRMC |
| a. REPORT<br>U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | b. ABSTRACT<br>U | c. THIS PAGE<br>U        |                                      |                                                          | 19b. TELEPHONE NUMBER (include area code)  |

# Table of Contents

|                                       | Page      |
|---------------------------------------|-----------|
| <b>Introduction</b>                   | <b>1</b>  |
| <b>Body</b>                           | <b>2</b>  |
| <b>Key Research Accomplishments</b>   | <b>8</b>  |
| <b>Reportable Outcomes</b>            | <b>8</b>  |
| <b>Conclusions</b>                    | <b>9</b>  |
| <b>References</b>                     | <b>10</b> |
| <b>Appendices and Supporting Data</b> | <b>14</b> |

## 1. INTRODUCTION

We and others have shown that *ETS*-related gene (*ERG*) proto-oncogene is overexpressed in prostate cancer (CaP) transcriptome using microdissected prostate tumor specimens (Ernst *et al.*, 2002; Vanaja *et al.*, 2003; Petrovics *et al.*, 2005). Our studies focusing on comparative quantitative expression of *ERG* in epithelial cells of matched benign and malignant prostate cells from a large patient cohort highlighted that CaP cells harbor frequent overexpression of *ERG* (60-70%) (Petrovics *et al.*, 2005). Among genomic rearrangements described in prostate cancer (CaP), *TMPRSS2-ERG* genomic fusion is the most common mechanism of oncogenic activation (Kumar-Sinha *et al.*, 2008). This gene rearrangement (Tomlins *et al.*, 2005) is due to the fusion of the androgen regulated *TMPRSS2* promoter (Lin *et al.*, 1999; Nelson *et al.*, 1999) to the *ERG* proto-oncogene protein coding sequences (Reddy *et al.*, 1987; Rao *et al.*, 1987) in CaP. Detection and characterization of the *ERG* oncoprotein in CaP and other neoplasms was recently reported by our group (Furusato *et al.*, 2010; Miettinen *et al.*, 2011) and by others (Park *et al.*, 2010; Yaskiv *et al.* 2011; Magi-Galluzzi *et al.*, 2011; Minner *et al.*, 2011). Activation of *ERG* has been increasingly recognized as a potentially causal oncogenic alteration (Klezovitch *et al.*, 2008; Tomlins, *et al.*, 2008; Sun *et al.*, 2008; Carver *et al.*, 2009; King *et al.*, 2009; Goldstein *et al.*, 2010). *ERG* gene is a member of the *ETS* family of transcription factors showing diverse expression patterns in human tissues (Turner and Watson, 2008). *ERG*, similar to other members of the *ETS* family has been described as a mediator of mitogenic signals, such as, mitogen activator protein kinases (Hart *et al.*, 1995). The multi-exon (17 exons) structure of *ERG* spans about 300 kb, and is transcribed to nine alternative splice variants and isoforms by a combination of alternative transcription initiation, mRNA splicing and transcription termination. The translated products of various *ERG* transcripts can function as oncoproteins with transforming activity (Rao *et al.*, 1987; Sementchenko *et al.*, 1998; Oikawa and Yamada, 2003; Rainis *et al.*, 2005). Thus, due to the functional significance in prostate cancer *ERG* continues to be the subject of intense research investigations. In recent years various *ERG* RNA splice variants have been described, and their relative abundance in CaP cells have been examined (Wang *et al.*, 2006 and 2008, Hu *et al.*, 2008). However, much remains to be defined with respect to *ERG* function in the context of CaP. This knowledge will further our understanding of *ERG* towards its clinical utility including patient stratification, treatment monitoring and therapeutic targeting of CaP.

**Towards these goals, we proposed the following specific aims:**

*#1 Characterization of full length sequences of TMPRSS2-ERG transcripts.*

*#2 Quantitative evaluations of selected TMPRSS2-ERG variants in CaP specimens and prognostic features.*

*#3 Defining the functional significance of specific splice variants of the rearranged ERG locus in CaP.*

**The hypothesis of this proposal is that specific *ERG* splice forms in *TMPRSS2-ERG* fusion configuration are selectively expressed in CaP cells and are functionally relevant in CaP. Since the discovery of *TMPRSS2-ERG* fusions, several fusion transcripts were identified by our and**

other laboratories. The expressions of these transcripts were shown to be associated with poor prognosis in previous studies (Wang *et al.*, 2006 and 2008; Hu *et al.*, 2008). However, careful evaluation of individual full length *TMPRSS2-ERG* transcripts is necessary to understand their biologic functions. Towards defining the functional association, we have generated a cDNA library from tumor specimens of CaP patients to identify and isolate full length *TMPRSS2-ERG* transcripts including the specific splice variants of *ERG* in CaP cells. Characterization of structure and identification of functions of full length *TMPRSS2-ERG* transcripts in CaP will lead to a major advancement in understanding the role of *ERG* in prostate tumor biology.

## 2. **BODY**

The progress reported here reflects major advances towards our understanding of key *TMPRSS2-ERG* splice variants expressed in prostate cancer cells

### 2-1. **Summary of Aims and Completed Tasks**

**Aim #1: Characterization of full length sequences of *TMPRSS2-ERG* transcripts in prostate cancer.** Overall aim was to perform innovative analyses of CPDR-CaP- library (at least 1,000,000 pfus) that would facilitate the identification of relatively common *TMPRSS2-ERG* splice and fusion variants in human CaP.

#### **Completed Tasks**

*CPDR CaP library was screened with *ERG* cDNA probe and by *TMPRSS2* probe to enrich for *TMPRSS2-ERG* fusion cDNA clones.*

*RACE experiments were performed to identify the authentic UTRs from the mRNA pool from CaP patient specimens. Using phage excision strategy, we generated plasmid (cDNA) clones.*

*DNA sequence of the clones was determined and the sequences were evaluated for open reading frames to identify *TMPRSS2-ERG* fusion variants and other *ERG* splice variants.*

**Aim #2: Quantitative evaluations of selected *TMPRSS2-ERG* variants in prostate cancer specimens and prognostic features.**

Towards this objective, we proposed to perform parallel quantitative analyses of up to 6 selected most abundant *TMPRSS2-ERG* variants in LCM tumor and matching benign epithelial cells from 150 patients representing primary prostate cancer specimens.

We proposed the quantitative expression of the most abundant *TMPRSS2-ERG* variants with clinico-pathologic parameters including patient age, race, pre-treatment PSA level, Gleason score, CaP family history, tumor stage, surgical margin status, seminal vesicle invasion, PSA recurrence,

bone metastasis, nuclear grade, differentiation, and a follow-up for cancer recurrence by serum PSA after surgery PSA doubling time and prostate cancer associated death.

Furthermore, we proposed to assess the associations of certain ERG transcript variants with genomic deletions associating with poor prognosis by using FISH (fluorescence in situ hybridization).

### **Completed Tasks**

*Quantitative RT-PCR analyses of fusion transcripts from 122 evaluable patients have shown the relative abundance of five main ERG transcripts in prostate tumor cells.*

*Significant correlation was found between increased ratios of type I ERG (ERG1-3) over type II (ERG8 and TEPC1) splice variants and higher Gleason sum and poorly differentiated phenotype.*

*Towards detecting genomic deletions, FISH assays were performed. TMPRSS2-ERG genomic rearrangements in the sections of primary tumors were examined for TMPRSS2-ERG genomic fusion by dual-color interphase FISH.*

**Aim #3: Defining the functional significance of specific splice variants of the cancerous ERG locus.** In VCaP cell culture model system, we proposed to assess whether TMPRSS2-ERG variants (Type I and Type II) contribute to the net oncogenic effect of ERG. Since the key objectives of Aim 1 and 2 are completed, we are now focused on this aim.

We proposed the evaluation of multiple inhibitory siRNA molecules for specifically targeting specific ERG splice variants expressed in CaP. Experimental objectives were to determine dose response and kinetic measures of inhibition efficacy for each siRNA by measuring the expression of specific TMPRSS2-ERG transcript and protein.

After selecting the most efficient siRNA molecules we planned to evaluate the combined effect of multiple siRNA molecules and measure dose response and kinetic characteristics.

We proposed that individual TMPRSS2-ERG variants (Type I and Type II) would be over expressed using TMPRSS2 promoter driven expression vectors in telomerase immortalized normal prostate cancer cells, such as, RC165 established in CPDR. Also, we proposed the evaluation of cancer biology related features (cell growth, soft agar colony formation, cell invasion and changes in cell cycle of cell) of the cells in response to knocking down or heterologous expression of specific TMPRSS2-ERG transcripts.

We proposed to test predicted protein products from Type I and Type II TMPRSS2-ERG transcripts for their ability and specificity to bind to target sequences in gel-shift experiments. We proposed to evaluate the regulatory efficiency of Type I and Type II products by using different known promoters (TGF $\beta$  type II receptor, MMP3 and collagen) by using luciferase assay systems.

### **Completed Tasks**


Inhibitory siRNA molecules were designed and prepared to specifically target the abundant *ERG8* (Type II) and *ERG1-3* (Type I) transcripts. The dose and kinetic assessment of siRNA molecules were performed for the inhibition of Type I and Type II transcripts.

Nuclear localization of transiently expressed in HEK293 cells were evaluated in the presence of *TMPRSS2-ERG3* and *TMPRSS2-ERG8* coded protein products of *ERG*.

The regulatory efficiency of Type I and Type II products were tested by using different *ERG* targeted promoters in luciferase assay systems.

## 2-2. Progress Highlights for the Reporting Period

**Identification of an *ERG8*-specific siRNA for the inhibition of the predominant Type II splice variant of *ERG*.** We have designed and evaluated specific siRNA molecules for knocking down the Type II splice variant *ERG8* in HEK293 cells transiently transfected with *TMPRSS2-ERG8* and *TMPRSS2-ERG3* expression vectors. The experiment revealed that inhibition of *ERG8* by siRNA significantly reduced the expression of *ERG8* protein levels in HEK293 cells. Towards the goals of this specific aim to generate siRNAs that specifically inhibit Type II variants we have generated a siRNA for the knockdown of *ERG8* without interfering with the expression of protein products of Type I transcripts.




**Figure 1.** Inhibition of *ERG8* protein in response to *ERG8* selective siRNA. We have designed siRNA molecules for targeting specific *ERG* splice variants and siRNAs were assayed for inhibiting *ERG8*. HEK293 cells were co-transfected with *TMPRSS2-ERG8* and *TMPRSS2-ERG3* expressing plasmid vectors and siRNA molecules targeting *ERG8*. Selective inhibition of the *ERG8* protein in immunoblot assay (right panel) demonstrates the identification of a siRNA specific for *ERG8*. The *ERG3* protein, encoded by Type I was unaffected by *ERG8* siRNA.

**Evaluation of the transcription regulatory function of Type I and Type II products by using luciferase assay systems.** The Myocyte Enhancer Factor 2 (MEF2) family of transcription factors are expressed in multiple cell types and are important regulators of development and differentiation (DeVal *et.al*, 2004; Wei *et al.*, 2010). The enhancer from the mouse *mef2c* gene is a well characterized enhancer that has been shown to be active in the vascular endothelium during embryogenesis and in adulthood where endogenous *ERG* protein is highly expressed (Mohamed *et al.*, 2010; Furusato *et al.*, 2010). Therefore, to evaluate the transcriptional regulatory function of *ERG* splice variants, we have utilized the *mef2c* vascular endothelial enhancer sequence, which harbors a cluster of four conserved elements for ETS factors, including *ERG*. Although we had

originally intended to use other regulatory sequences (*TGF-beta*, *MMP3* and *collagen*), on the basis studies of *mef2c* gene expression regulation, we anticipated a strong reporter read out using *mef2c*


enhancer based luciferase reporter construct when transcriptional regulatory activities of *ERG* splice variants were assayed. The *mef2c* enhancer was cloned into the pGL4.24[*luc2P*/minP] vector that carries a minimal promoter upstream of the luciferase reporter gene *luc2P*, which is designed for high expression, reduced anomalous transcription and sensitivity to activation and repression.



**Figure 2.** Design of a Luciferase reporter vector by using the mouse *mef2c* vascular endothelial enhancer for evaluation of transcriptional regulatory function of *ERG* variants.


The pGL4.24-*mef2c*-[*luc2P*/minP] reporter construct was co-transfected with 40 ng and 80 ng of expression vectors encoding Type I and Type II *ERG* proteins in HEK293 cells. Both the full length (*ERG3*) and the N-terminus truncated proteins (products of *TM*PRSS2-*ERG* fusion) expressed activated the transcription from the *mef2c* driven luciferase reporter construct. However, activation by the N-terminus truncated *ERG3* protein is 10-20% lower than activation by the full length protein. Consistent with the absence of nuclear localization signal in Type II encoded *ERG8*,

this *ERG* variant did not alter the basal promoter activity of the reporter construct.




**Figure 3.** Type I transcript encoded *ERG* protein (*ERG3* and the N-terminus truncated *ERG3* protein, *TM-ERG3*) activates the transcription of luciferase reporter through the *mef2c* promoter in a dose dependent manner. Consistent with the absence of nuclear localization signal in Type II encoded *ERG*, *ERG8* does not alter the basal promoter activity of the reporter construct.

In an experiment addressing the interaction of *Type I* and *Type II* splice variants towards Specific Aim #3 we co-transfected *TPRSS2-ERG3* and increasing concentrations of *TPRSS2-ERG8* expression vectors in HEK293 cells. We found a dose dependent inhibition of ERG3-mediated activation of reporter in response to increasing doses of *ERG8*. This observation support the central hypothesis of our proposal that the *Type II* splice form may interfere with *Type I* function. However, further experiments are needed to follow up on these preliminary observations.



**Figure 4.** Dose dependent abrogation of ERG3 (*Type I*)-mediated transcriptional activation by increasing concentrations of ERG8 (*Type II*). HEK293 cells were co-transfected with *TPRSS2-ERG3* and 0, 50 and 150 ng of *TPRSS2-ERG8* expression vector. Luciferase activity was measured in light units and normalized to the control (0 ng of *TPRSS2-ERG8* vector).


**Expression of ERG proteins in cell lines** The highly-specific anti-ERG monoclonal antibody (CPDR ERG-MAb) developed in our laboratory recognizes ERG proteins encoded by both type I and II splice variants, this antibody has provided a unique opportunity for the evaluation of all ERG protein forms in prostate and other cancers (Furusato *et al.*, 2010; Miettinen *et al.*, 2011). In this reporting period we have further evaluated ERG protein translated from Type I and Type II splice variants in various cancer cell lines. We have examined the androgen inducible expression of ERG



**Figure 5.** Androgen dose dependent expression of ERG3 protein, a product of *Type I* splice variant and the expression of a 38 kDa ERG protein matching the expected size of ERG8 (*Type II*).


proteins in *TPRSS2-ERG* harboring VCaP cell line in response to increasing doses of the synthetic androgen hormone R1881. As expected, we observed the dose dependent increase in ERG3 protein expression. Under these experimental conditions, we also observed the increased expression of a protein product with molecular weight similar to the protein product of *Type II* transcript, ERG8. This observation further highlights the need for the evaluations of ERG 8 protein that has not been studies before.

Similarly, we have observed ERG3 and shorter protein products in cell lines derived from diverse cancers: acute myeloid leukemia, KG-1; colon cancer, COLO 320; acute T lymphoblast leukemia, MOLT4; and prostate cancer, VCaP cells. In addition to the expression of Type I splice variant product we consistently detected shorter protein products. The relation to the Type II splice variant ERG8 to the observed protein products will be further examined.



**Figure 6.** Detection of ERG protein in prostate and non-prostate cancer cell lines CPDR ERG-MAb. ERG protein expression was analyzed by using cell lysates from cell lines derived from diverse cancers: Jurkat (acute T cell leukemia); MCF7 (breast cancer), KG1 (acute myelogenous leukemia), COLO320 (colon carcinoma); MOLT-4 (acute lymphoblastic leukemia); VC-NT (VCaP prostate cancer cells treated with non target siRNA); VC-si-1 (VCaP prostate cancer cells treated with ERG specific siRNA). LNCaP (prostate cancer cell line, Jurkat, MCF7 and LNCaP cells were used as negative controls.

**Temporal/spatial expression of ERG proteins in developing mouse.** As discussed above the highly-specific anti-ERG monoclonal antibody (CPDR ERG-MAb) developed in our laboratory recognizes ERG proteins encoded by both *type I* and *II* splice variants. Using this antibody, we have established Erg protein in developing and adult mouse tissues. Most striking of these observations was highly selective and abundant expression of erg protein in endothelial cells of mouse tissues. We for the first time clarified that endogenous ERG was not expressed in normal mouse prostate epithelium (Mohamed *et al.*, 2010). Similar findings were noted for human prostate (Furusato *et al.*, 2010). These observations underscored cancer specific aberrant expression and function of ERG in prostate epithelium.



**Figure 7.** Widespread immunolocalization of Erg proteins was observed in endothelial cells and restricted expression in precartilaginous and hematopoietic tissues. Erg is not expressed in any epithelial tissue including prostate epithelium (lower panels), or in infiltrating lymphocytes that are occasionally seen in the prostate environment, a common site of tumors with ERG rearrangements and unscheduled ERG expression.

To assess the Type II splice variant, ERG8, we have developed a rabbit polyclonal anti-ERG8 antibody. Initial characterization of the anti-ERG8 antibody confirmed the specificity of the antibody in detecting ERG8 protein by Western blot assays. This antibody will be further evaluated.

### **3. KEY RESEARCH ACCOMPLISHMENTS**

- Transcriptional regulatory activities of *ERG* splice variants were assayed by using murine *mef2c* promoter-luciferase reporter construct. Type I variant encoded ERG3 protein activates the transcription of luciferase reporter through the *mef2c* enhancer. In contrast, type II encoded ERG8 does not alter the basal promoter activity.
- We have delineated the temporal and spatial expression profile of ERG oncoprotein during mouse embryo development by using the highly specific CPDR ERG-MAb developed by our laboratory.
- Erg is not expressed in any normal epithelial tissue including prostate epithelium, or in infiltrating lymphocytes that are occasionally seen in the prostate environment, a common site of tumors with ERG rearrangements and unscheduled ERG expression.
- We have developed ERG 8 selective siRNAs and antibodies which will facilitate ERG8 expression and functions.

**To complete Specific Aim #3, the following experiments are in progress and will be performed in the next reporting period.** While we have successfully accomplished several key objectives of the grant proposal, with the unscheduled early departure of the post-doctoral fellow primarily assigned to this project within the approved extension we will complete 1) the molecular and biological assessment of delivering inhibitory molecules with targeting prognostically relevant fusion transcripts in *TMPRSS2-ERG* harboring VCaP cells; 2) we will assess changes in cell growth, invasion and differentiation characteristics of normal prostate cells in response to the ectopic expression of *TMPRSS2-ERG* splice variants; 3) predicted protein product of *TMPRSS2-ERG* splice variants will be tested for their ability and specificity to regulate different known promoters and for their sub-cellular localization.

### **4. REPORTABLE OUTCOMES**

#### **4-1. Publication**

Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath TL. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer. 2010 Oct 25;1:197-208.

#### **4-2. Patent Application**

ERG Monoclonal Antibodies. PCT/US2010/032714 , WO/2010/126972, published on November 4, 2010.

#### **4-3. Press Release**

None

#### **4-4. Poster presentations**

##### **DoD-PCRP IMPACT Meeting 2011**

Structure and Function of the Splice Variants of TMPRSS2-ERG, Prevalent Genomic Alteration in Prostate Cancer.

Taduru Sreenath, Albert Dobi, Ying Hu, Shyh-Han Tan, Yongmei Chen, Chen Sun, Isabell A. Sesterhenn, David G. McLeod, Gyorgy Petrovics and Shiv Srivastava

Sub-cellular Localization and Transcriptional Activity of ERG Protein Encoded by the Common *TMPRSS2-ERG* Splice Variants Expressed in Prostate Cancer.

Zainab Afzal, Tseday Zewdu Tegegn, Ahmed Mohamed, Taduru Sreenath, Deepak Kumar, Shiv Srivastava and Shyh-Han Tan

##### **AACR Annual Meeting, 2011**

ETS-Related Gene (ERG) Expression in Developing and Adult Mouse Tissues

Ahmed A. Mohamed, Shyh-Han Tan, Natallia Mikhalkovich, Sathibalan Ponniah, Valeri Vasioukhin, Charles J. Bieberich, Isabell A. Sesterhenn, Albert Dobi, Shiv Srivastava and Taduru L. Sreenath

#### **5. CONCLUSIONS**

- Identification of *TMPRSS2-ERG*, *Type I*, which encodes full-length ERG protein consisting SAM and ETS domains (ERG1, ERG2, ERG3), and *Type II*, encoding ERG proteins lacking the ETS domain (ERG8 and a new variant, TEPC)
- Quantitative RT-PCR analyses of fusion transcripts from 122 patients showing relative abundance of ERG *Type I* and *Type II* splice variants
- Increased ratio of *Type I* over *Type II* variants showing correlation with poorly differentiated pathology /high Gleason score and outcome

- Transient expression in HEK293 cells revealed the presence of *TMPRSS2-ERG3* encoded protein (Type I) in the nucleus and *TMPRSS2-ERG8* encoded protein (Type II) in the cytoplasm
- Successful developed of a siRNA for the inhibition of ERG8 *Type II* splice variant.
- Demonstration that ERG3 a product of *Type I* splice variant, transcriptionally activates gene expression through ETS-regulated enhancer and co-transfection of the ERG8 expressing *Type II* splice variant abrogates the transcriptional activator function of ERG3 (*Type I*).
- Generation of a novel rabbit polyclonal antibody for detecting ERG8 protein in human prostate cancer specimens and currently evaluating this antibody.
- Delineation of the expression of Erg protein during development. Demonstrated normal expression of ERG protein in endothelial cells, and transient expression in precartilaginous and hematopoietic tissues. Revealed that ERG is not expressed in normal epithelial tissues including normal prostate epithelium.

## 6. REFERENCES

Carver, B.S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P.T., *et al.* (2009). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. *Nat Genet* 41, 619-624.

De Val, S., Anderson, J.P., Heidt, A.B., Khiem, D., Xu, S.M., and Black, B.L. (2004). Mef2c is activated directly by Ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer. *Developmental biology* 275, 424-434.

Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klären R, Gröne EF, Wiesel M, Güdemann C, Küster J, Schott W, Staehler G, Kretzler M, Hollstein M, Gröne HJ. (2002) Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. *Am J Pathol.* 160, 2169-80.

Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA. (2010) ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. *Prostate Cancer Prostatic Dis.* 3, 228-37.

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. (2010) Identification of a cell of origin for human prostate cancer. *Science.* 329, 568-71.

Hart, A.H., Corrick, C.M., Tymms, M.J., Hertzog, P.J., and Kola, I. (1995). Human ERG is a proto-oncogene with mitogenic and transforming activity. *Oncogene* 10, 1423-1430.

Hu, Y., Dobi, A., Sreenath, T., Cook, C., Tadase, A.Y., Ravindranath, L., Cullen, J., Furusato, B., Chen, Y., Thangapazham, R.L., *et al.* (2008). Delineation of TMPRSS2-ERG splice variants in prostate cancer. *Clin Cancer Res* 14, 4719-4725.

Kumar-Sinha, C., Tomlins, S.A., and Chinnaiyan, A.M. (2008). Recurrent gene fusions in prostate cancer. *Nat Rev Cancer* 8, 497-511.

King, J.C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B.S., Leung, D.H., Taylor, B.S., Sander, C., Cardiff, R.D., Couto, S.S., *et al.* (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. *Nat Genet* 41, 524-526.

Klezovitch, O., Risk, M., Coleman, I., Lucas, J.M., Null, M., True, L.D., Nelson, P.S., and Vasioukhin, V. (2008). A causal role for ERG in neoplastic transformation of prostate epithelium. *Proc Natl Acad Sci U S A* 105, 2105-2110.

Lin, B., Ferguson, C., White, J.T., Wang, S., Vessella, R., True, L.D., Hood, L., and Nelson, P.S. (1999). Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. *Cancer Res* 59, 4180-4184.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M. (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. *Prostate*. 71, 489-97.

Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn I. (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. *Am J Surg Pathol*. 35, 432-41.

Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, Brase JC, Liu A, Schluter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T. (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapy. *Clin Cancer Res*. [E-pub ahead of print] PMID: 21791629.

Mohamed AA, Tan S-H, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath TL. (2010) Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody. *Journal of Cancer* 1, 197-208.

Nelson, P.S., Gan, L., Ferguson, C., Moss, P., Gelinas, R., Hood, L., and Wang, K. (1999). Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. *Proc Natl Acad Sci U S A* 96, 3114-3119.

Oikawa, T., and Yamada, T. (2003). Molecular biology of the Ets family of transcription factors. *Gene* 303, 11-34.

Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA. (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. *Neoplasia*. 12, 590-8.

Petrovics, G., Liu, A., Shaheduzzaman, S., Furusato, B., Sun, C., Chen, Y., Nau, M., Ravindranath, L., Dobi, A., Srikantan, V., *et al.* (2005). Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. *Oncogene* 24, 3847-3852.

Rainis, L., Toki, T., Pimanda, J.E., Rosenthal, E., Machol, K., Strehl, S., Gottgens, B., Ito, E., and Izraeli, S. (2005). The proto-oncogene ERG in megakaryoblastic leukemias. *Cancer Res* 65, 7596-7602.

Rao, V.N., Papas, T.S., and Reddy, E.S. (1987). Erg, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. *Science* 237, 635-639.

Reddy, E. S. P., V. N. Rao, and T. S. Papas. (1987) The ERG gene: a human gene related to the ets oncogene. *Proc. Natl. Acad. Sci. USA* 84:6131-6135.

Sementchenko, V.I., Schweinfest, C.W., Papas, T.S., and Watson, D.K. (1998). ETS2 function is required to maintain the transformed state of human prostate cancer cells. *Oncogene* 17, 2883-2888.

Sun, C., Dobi, A., Mohamed, A., Li, H., Thangapazham, R.L., Furusato, B., Shaheduzzaman, S., Tan, S.H., Vaidyanathan, G., Whitman, E., *et al.* (2008). TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. *Oncogene* 27, 5348-5353.

Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., *et al.* (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 310, 644-648.

Tomlins, S.A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B.E., Cao, Q., Prensner, J.R., Rubin, M.A., Shah, R.B., *et al.* (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia* 10, 177-188.

Turner, D.P., and Watson, D.K. (2008). ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. *Expert Rev Anticancer Ther* 8, 33-42.

Vanaja DK, Cheville JC, Iturria SJ, Young CY. (2003) Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. *Cancer Res.* 63, 3877-82.

Wang J, Cai Y, Ren C, Ittmann M. (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. *Cancer Res.* 66, 8347-51.

Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. *Cancer Res.* 68, 8516-24.

Wei, G.H., Badis, G., Berger, M.F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A.R., et al. (2010). Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. *The EMBO journal* 29, 2147-2160.

Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S, Chen L, Magi-Galluzzi C, Zhou M. (2011) The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. *Am J Surg Pathol.* 35, 1062-8.

## **7. APPENDICES AND SUPPORTING DATA**

## Research Paper

# Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody

Ahmed A. Mohamed<sup>1</sup>, Shyh-Han Tan<sup>1</sup>, Natallia Mikhalkevich<sup>1</sup>, Sathibalan Ponniah<sup>2</sup>, Valeri Vasioukhin<sup>3</sup>, Charles J. Bieberich<sup>4</sup>, Isabell A. Sesterhenn<sup>5</sup>, Albert Dobi<sup>1</sup>, Shiv Srivastava<sup>1</sup> and Taduru L. Sreenath<sup>1</sup>✉

1. Center For Prostate Disease Research, Department of Surgery, United States Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda MD 20814, USA
2. Cancer Vaccine Development Laboratory, Department of Surgery, United States Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda MD 20814, USA
3. Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
4. Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA
5. Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, DC, USA.

✉ Corresponding author: Taduru L. Sreenath, Ph.D., Department of Surgery, Uniformed Services University. Phone: (301) 295-9821; Fax: (240) 453-8912; E-mail: tsreenath@cpdr.org

Received: 2010.10.12; Accepted: 2010.10.24; Published: 2010.10.25

## Abstract

Oncogenic activation of the ETS Related Gene (*ERG*) in humans was originally identified in subsets of Ewing sarcomas, myeloid leukemias and, recently, in the majority of prostate cancers. Expression of human ERG protein and consequently its functions in normal and disease states needs to be better understood in light of its suggested role in cell differentiation and proliferation. Here, we analyzed temporal and spatial expression of the Erg (mouse protein) by immunohistochemical analysis during mouse embryonic and adult organogenesis using a highly specific ERG monoclonal antibody (ERG MAb). This study establishes widespread immunolocalization of Erg protein in endothelial cells and restricted expression in precartilaginous and hematopoietic tissues. Intriguingly, Erg is not expressed in any epithelial tissue including prostate epithelium, or in infiltrating lymphocytes that are occasionally seen in the prostate environment, a common site of tumors with *ERG* rearrangements and unscheduled *ERG* expression. These findings will further aid in investigations of Erg functions in normal and disease conditions.

Key words: Ets Related Gene, ERG, Expression, ERG MAb, Mouse, Development.

## Introduction

Chromosomal translocations leading to gene fusions have been well characterized in variety of malignancies [1]. Gene fusions often result in chimeric proteins with aberrant functions and/or ectopic expression. Frequent elevated expression of the *ETS* related genes (*ERG*) due to chromosomal rearrangements resulting into the fusion between androgen regulated promoters (predominantly *TMPRSS2*) and protein coding sequence of *ETS* transcription factors

has been established in prostate cancer [2, 3]. *ETS* (Erythroblast Transformation Specific family of transcription factors) genes are a large family with at least thirty members that function as transcription factors [4]. All *ETS* transcription factors share a highly conserved DNA binding domain, the ETS domain [5] and at least *Ets1*, *Erg*, *Fli1* and *Etv2* are expressed in embryonic endothelial cells of mouse [6, 7]. *ERG* is well conserved in evolution and its expression and poten-

tial functions have been studied in xenopus, zebrafish, mouse and humans [8-12]. The results from these studies suggest an emerging role for *ERG* in the transcriptional regulation of endothelial specific genes [13-16] and in definitive hematopoiesis [17, 18]. Both hematopoietic and endothelial cells are of mesodermal origin and are derived from the hemangioblast, a common precursor, suggesting a shared developmental pathway [19]. Knock-down of *Erg* is associated with a significant reduction in the formation of vascular structures and the number of endothelial cells [20] and with apoptosis [21]. These studies indicate that *Erg* may have important implications in vascular development during mouse embryogenesis. Although *Erg* does not appear to be required for hematopoiesis during embryonic stem cell differentiation, it may play a role in endothelial cell differentiation [20]. Hematopoietic stem cells give rise to both T- and B-lymphocytes in embryogenesis and throughout adult life. Although mature T-lymphocytes do not express *Erg*, expression is detected transiently during T-lineage specification and is silenced after their commitment [22]. During B-cell development in the mouse, *Erg* expression was detected in early pre-B cells, pre-B and in mature B cells [23]. In developing mouse, *Erg* mRNA is expressed in mesodermal tissues such as endothelial cells, mesenchymal condensations during precartilaginous depositions, and in urogenital regions [11]. All of the expression studies were carried out by using RT-PCR or in situ hybridization. However, the protein expression and its cellular distributions could not be performed due to a lack of an *Erg*-specific antibody.

The goal of this study was to establish the expression pattern of *Erg* protein in developing and adult mouse tissues by using an *ERG*-specific antibody. These data would serve as a basis to understand the function of *Erg* during normal development in many organs and pathological conditions, such as its cancer-specific expression in prostatic adenocarcinoma. Although several antibodies for detecting human *ERG* protein and mouse *Erg* protein have been described, due to high degree of homology among *ETS* family members, in particular its closest homologue *Fli-1*, antibody cross reactivity has become a major concern in detection of the *ERG* protein. Recently, we have generated and characterized an *ERG*-specific mouse monoclonal antibody that showed high specificity towards *ERG* protein that does not cross react with *FLI-1* protein [24]. In the present study, we examined the detailed expression of the *Erg* protein during prenatal and adult mouse organogenesis.

## Results and discussion


**Evaluation of *ERG* Monoclonal Antibodies for the Specificity of *ERG* Protein Detection:** We evaluated the specificity of three recently available *ERG* monoclonal antibodies including the *ERG* MAb that we recently reported [24]. As noted previously, the *ERG* MAb detected *ERG* protein products in MOLT4, KG1, COLO 320 and VCaP tumor cell lines, whereas LNCaP, MCF7 and Jurkat cell lines were negative for *ERG*. The *ERG* MAb did not show cross reactivity to *FLI-1* in LNCaP cells infected with a *FLI-1* adenovirus expression vector (Fig 1A). Under similar assay conditions, rabbit monoclonal antibodies to *ERG* (EPR 3864 and EPR 3863) obtained from Epitomics (Burlingame, CA) detected *FLI-1* in LNCaP cells infected with a *FLI-1* adenovirus expression vector (Fig 1B, 1C). In addition, a rabbit monoclonal *ERG* antibody EPR 3864 detected a protein in Jurkat cell line (acute T cell leukemia) that was not recognized by either the rabbit monoclonal antibody EPR 3863 or our *ERG* MAb suggesting potential cross reactivity to other *ETS* related proteins by EPR 3864. Interestingly, other monoclonal *ERG* antibody EPR 3863 recognized *FLI-1* in LNCaP cells infected with a *FLI-1* adenovirus expression vector. Taken together, the results obtained from immunoblot analyses suggest that the *ERG* MAb we developed is highly specific for *ERG* protein detection and was further assessed in other immunoassays.

To determine the efficiency of *ERG* MAb antibody in a prostate tumor model, we analyzed *ERG* expression in *ERG*-positive VCaP and *ERG*-negative LNCaP prostate cancer cell tumor xenografts in SCID mice. The *ERG* MAb antibody detected *ERG* protein in VCaP xenografts, staining primarily the nuclei with some cytoplasmic reactivity (Fig 2A). As expected, *ERG* negative LNCaP xenografts did not show *ERG* expression. The endothelial cells lining the blood vessels and capillaries showed positive reactivity to *ERG* MAb in tumors as well as normal adjacent tissue (Fig 2B). Further, we evaluated the *ERG* MAb for the detection of *ERG* protein the prostates of *ERG*-transgenic mice [25]. Transgenic *ERG* expression was detected in the prostate luminal epithelial cells of *ERG*-transgenic mice (Fig 2C). In addition, endogenous *Erg* protein was detected only in the endothelial cells of blood vessels and capillaries (Fig 2D). Infiltrating lymphocytes did not show immune-reactivity to *ERG* MAb (Fig 2 E, G). Consistent with a recent report [26], rabbit monoclonal antibodies EPR 3864 showed a strong staining of lymphocytic infiltration in prostate gland (Fig 2F, H). Interestingly, both the rabbit monoclonal *ERG* antibodies (EPR 3864, EPR

3863) and FLI-1 antibodies have shown reactivity to infiltrating lymphocytes (Fig 2I, J). It is interesting to note that ERG is turned on at transition stage (between precursor and pro-T stage 1) of T-cell differentiation and does not persist stably to define T-cell identity, and is shut off after T cell lineage commitment [22, 27, 28]. In this study, we have not characterized the transient expression of Erg during T-cell development and differentiation.


To study the utility of the ERG MAb to detect the expression of ERG in cells using flow cytometry, seven human cancer cell lines, VCaP and LNCaP (prostate cancer), T2 and Jurkat (T lymphoblastoid cells), KG-1 and KG-1a (myeloblastic) were analyzed. All cell lines were permeabilized by standard cell intracellular staining methods by using detergent followed by incubation with the ERG MAb and secondary fluorochrome-conjugated antibodies. As

shown in Fig 3C and D, expression of ERG was clearly detectable in the TMPRSS2-ERG fusion-harboring VCaP cells and was not observed in the TMPRSS2-ERG negative LNCaP cells (Fig 3A, 3B). In the case of the hematopoietic/lymphoblastoid cancer cells of the T lymphocyte lineage, ERG expression was detected neither in T2 (Fig 3I, 3J) nor in Jurkat cells (Fig 3K, 3L). With the hematopoietic cell lines of myeloid lineage, KG-1 and KG-1a, the expression of ERG was clearly detectable in both cell lines (Fig 3E, 3F and Fig 3G, 3H). Interestingly, the KG-1a cells, which are considered to be less mature or differentiated than the KG-1 cells, expressed much higher amounts of the ERG protein. Taken together, the consistent results of Western blot, IHC and FACS assays established the specificity of the ERG MAb in detecting ERG protein in different assay platforms and biological specimen contexts.




**Figure 1:** Expression of human ERG protein in cancer-derived cell lines: ERG protein expression was analyzed by using total cell lysates from acute T cell leukemia (Jurkat), breast cancer cell line (MCF7) acute myelogenous leukemia cell line (KG1), colon carcinoma cells (COLO320), acute lymphoblastic leukemia (MOLT-4), ERG expressing prostate cancer cell line (VCaP) treated with non target siRNA (VCaP-NT), prostate cancer cell line (VCaP) treated with ERG specific siRNA (VCaP-ERG-si-1), prostate cancer cell line LNCaP, prostate cancer cell line LNCaP transduced with adenoviral FLI-1 expression vector. Extracted proteins were processed for immunoblot assay by using (A) mouse monoclonal ERG antibodies ERG MAb, (B) rabbit monoclonal anti-ERG antibodies EPR 3864 Cat.No 2805-I, (C). Rabbit monoclonal anti-ERG antibodies EPR 3863 Cat.No 2849-I. Note the lack of immunoreactivity to the protein extracts from Jurkat, LNCaP and LNCaP transduced with adenoviral Flt-1 expression vector with ERG MAb in panel A, and reactivity with other antibodies in panel B and C.

**Figure 2:** Expression of ERG protein in FFPE tissue: ERG protein expression in (A) VCaP and (B) LNCaP xenograft tumors obtained from SCID mice. Strong expression of ERG in VCaP cells (black arrow). ERG staining is seen only in the endothelial cells (arrow) of LNCaP tumors but not in the epithelial cells. Expression of ERG protein is detectable in the ARR2PBΔERG transgenic mouse prostates (C) compared to wild-type littermate control (D). Infiltrating lymphocytes are occasionally seen in the prostate glands and show no reactivity to ERG MAb (E, G). However, strong staining is seen in the infiltrating lymphocytes with Epitomics EPR 3864 (F, H), EPR 3863 (I) and FLII antibody (J).




**Figure 3.** ERG expression in cancer cell lines. Intracellular staining was carried out in permeabilized cells with an IgG1 isotype control antibody (A, C, E, G, I and K) or for ERG with ERG MAb (B, D, F, H, J and L) and detected by using FITC-conjugated secondary antibody and flow cytometry analysis.




**Erg protein expression in prenatal mouse development:** During E9.5d, strong expression of Erg protein was detected by the ERG MAb mainly in the endothelial cells of blood vessels around the neural tube (Fig 4A, 4B). Additionally, expression was also prominent in the cells that line the amnion (Fig 4A). At this stage, during heart development, the ventricle begins trabeculation to demarcate this region from the primitive heart. Expression of Erg was observed in endothelial cells that line the trabeculated regions of the ventricle (Fig 4C). Endothelial cells present in the inter-somitic capillaries show strong expression of Erg (Fig 4D). Similar endothelial-specific expression was found in the dorsal aorta and around the neural tube (Fig 4E). The distribution observed with ERG MAb antibody is consistent with earlier reported studies of *Erg* mRNA expression [11, 20]. Similar to earlier stages of development, at E12.5d, Erg expression was endothelial cell-specific in the majority of the tissues (Fig 5). In addition to endothelial expression, Erg expression was detected in the precartilaginous/ cartilage primordium of the nasal septum, neural arch and rib

(Fig 5A, 5B, 5C). Mesenchymal condensations are required at this stage to initiate the paving cartilage path for both transient and permanent cartilage. The transient cartilage will undergo ossification to form bone. Interestingly, Erg expression was observed only in the precartilaginous primordium suggesting that Erg may have critical role in the differentiation of cartilage. Heart development at this stage exhibited extensive trabeculation of the ventricle and showed clear lining of endothelial cells with positive Erg staining along the trabeculated endocardium (Fig 5B). Lungs at this stage were not yet divided into lobes and the stroma with enriched capillaries exhibited strong expression of Erg in developing lung (Fig 5D). Epithelial cells of segmental bronchus did not show Erg expression (Fig 5D). Kidney at this stage starts subdividing into cortical and medullary regions. Expression was detected only in the blood vessels and capillaries uniformly throughout the kidney and not in the kidney cortex or medulla (Fig 5E).



**Figure 4.** Expression pattern of Erg protein during mouse embryogenesis (E9.5d): Embryonic 9.5d mouse showing the expression of Erg protein by immunohistochemistry with ERG MAb. (A) Coronal section of an E9.5 embryo showing a specific staining in blood vessels (bv), inter-somitic vessels (is) and in the amnion (am). (B) Higher magnification of hind brain. Expression is not seen in the hind brain (hb), neural tube (nt) and optic vesicle (o). (C). Higher magnification of ventricle (vt) region of the heart showing strong signal in the endothelial cells (ec) along the trabeculated endocardium. (D) Higher magnification of somites in the caudal region showing Erg expression in the inter-somatic blood vessels (sv). (E). Tail region of the embryo showing neural tube (nt), midline dorsal aorta (mda). Erg expression was detectable only in the endothelial cells of dorsal aorta. Somites (s).



**Figure 5.** Expression pattern of Erg protein during mouse embryogenesis: (E12.5). (A) Sagittal section of an E12.5d embryo showing a specific staining in cartilage primordium (cp) of the nasal septum (ns), and the mid shaft region of the rib (rb). (B) Higher magnification of ventricle (vt) region of the heart showing strong expression in the endothelial cells (ec) along the trabeculated endocardium. (C) Erg protein was detectable in the precartilage condensations in the neural arch (na). (D) Higher magnification of developing lungs (not yet divided into lobes) show lack of expression in the epithelial cells of segmental bronchus (sb). Surrounding stroma with enriched capillaries exhibit strong staining. (E). Expression is seen only in endothelial cells of the blood vessels and capillaries uniform throughout the kidney.


Erg expression in E14.5d was found mostly in the endothelial cells of variety of tissues (Fig 6). In developing liver, about 1-2% of liver cells exhibited reactivity with ERG MAb antibody and megakaryocytes did not show Erg expression. Expression in the cartilage appeared to be reduced significantly compared to E12.5d in the rib, nasal septum and vertebrae. We found significant differences between ERG MAb and rabbit monoclonal ERG antibodies EPR 3864 megakaryocytic immunostaining. No significant changes in the Erg expression patterns were observed in the later stages of mouse development. As the overexpression of ERG in the prostate is implicated in the oncogenic process, we examined the normal expression of Erg protein in developing prostate glands. In the mouse, the prostatic buds first emerge at the rostral end of the urogenital sinus at approximately 17.5 days of gestation and subsequently, the prostatic epithelial buds undergo extensive ductal outgrowth and branching morphogenesis into the surrounding mesenchyme during the first three weeks of postnatal development. Interestingly, Erg staining was observed only in the mesenchymal compartment and restricted to capillary endothelial cells (Fig 7) suggesting that Erg may not be critical in normal prostate development or differentiation.

In liver of E17.5d mice, the expression of Erg is restricted to very few cells such as endothelial and other non-parenchymal cells which later differentiate into Kupffer cells and hepatic stellate cells. It is not clear at this stage which type of cells in addition to endothelial cells express Erg protein. Similar to E14.5d liver megakaryocytes, ERG MAb did not show reactivity with E17.5d hepatic megakaryocytes (Fig 8A). However, rabbit monoclonal ERG antibodies EPR 3864 showed a strong staining in megakaryocytes, in addition to endothelial and other cell types (Fig 8B).


**Expression of Erg protein in adult mice:** We extended our study to adult mouse tissues to analyze the expression of Erg protein (Fig 9). Similar to embryonic tissues, the expression of Erg was observed in the endothelial cells of the adrenal gland, cartilaginous component of bone, heart muscle, kidney, liver, lung, spleen urinary bladder. Erg expression was also evident in the lymphatic endothelial cells in adult mouse. As expected, expression was undetectable in the prostate epithelium. Detailed examination of these tissues has revealed that the expression was mostly restricted to hematopoietic and endothelial compartments. In liver, the expression appeared to be in the Kupffer cells. In bone marrow, ERG MAb did not show reactivity with megakaryocytes. Interestingly,

eosinophils, with a characteristic ring shaped or segmented/multilobed nuclei stained the nuclei with ERG MAb. Eosinophils are derived from hematopoietic stem cells initially committed to the myeloid line and then to the basophil-eosinophil granulocyte lineage. The presence of Erg in these cells suggest its potential function in either differentiation or maintenance of differentiation state. During development, Fli1 is preferentially expressed in hematopoietic cells, endothelial cells and in the mesenchyme which is mainly derived from neural crest cells [29]. Similar to earlier observations [11] we also observe the


co-expression of the *Erg* and *Fli1* genes in both endothelial and mesodermal tissues, including urogenital tract and precartilaginous areas. Similar to *Erg*, Fli1 expression also appeared transient during mouse embryogenesis. This result is consistent with subtle temporal regulation. Whether this spatiotemporal overlap determines redundant functions or not remains to be determined. Due to specificity and clarity of Erg detection in developing and adult mouse tissues, these findings will be valuable in further assessing in vivo functions of Erg in normal and malignant tissues.



**Figure 6.** Expression pattern of Erg protein during mouse embryogenesis (E14.5): (A) Sagittal section of an E14.5 embryo showing a specific staining in cartilage primordium (cp) of the nasal septum (ns) similar to E12.5d. Higher magnification of midbrain showing capillaries staining of Erg. (C) Higher magnification of ventricle (vt) region of the heart showing strong reactivity in the endothelial cells (ec) along the trabeculated endocardium. (D) Higher magnification of developing lungs shows lack of expression in the epithelial cells of segmental bronchus (sb). Stroma with enriched capillaires exhibit strong staining. (E). Higher magnification of adrenal gland with endothelial cell specific Erg staining.




**Figure 7.** Expression pattern of Erg protein during mouse embryogenesis(E17.5): (A) Ventricle showing trebeculated endocardium with endothelial specific staining of Erg. (B). High magnification of lung showing capillaries and blood vessel specific Erg reactivity. Note the lack of staining in the lung epithelial. (C) High magnification of liver showing a specific staining is non-hepatocytes in addition to endothelial cells. (D) High magnification of adrenal gland showing random Erg in both cortex and medullary region consistent with fenestrated vessels. Similarly, kidney (E) and intestine (F) show endothelial specific staining, Open arrows show the lack of expression in the bronchial epithelial cells (B), kidney tubules (E) and intestinal epithelial cells in the cripte (F). Blood vessel (bv), bronchial epithelium (be).



ERG MAb

ERG (EPR 3864 ) Epitomics

**Figure 8.** Expression of Erg protein in developing liver (E17.5). (A) Detection of Erg protein in endothelial and non-paranchymal cells by ERG MAb. The arrows point to megakaryocytes that lack the expression of Erg protein. (B). Erg staining with rabbit monoclonal ERG antibodies Epitomics EPR 3864 show endothelial and non-paranchymal cells staining. Megakaryocytes known to have expression of Fli1 also are detected with EPR 3864. Similar megakaryocyte specific expression is also observed with EPR 3863 and Fli1 antibodies (data not shown).



**Figure 9.** Expression of Erg protein in adult tissues: (A) Bone marrow (B) Liver (C) Lung (D) Pancreas (E) Lymphatic vessels (F) Spleen (G) Kidney (Glomeruli) (H) Thymus (I) Anterior prostate (J) Dorsal prostate (K) Lateral prostate (L) Ventral prostate. Expression is seen mainly in the endothelial cells in blood vessels and capillaries (arrows). In bone marrow, megakaryocyte show lack of Erg expression (open arrow).

## Materials and Methods

**Antibodies:** Recently, we have reported the generation and characterization of mouse monoclonal antibodies to ERG, showing higher specificity [24]. In this study, we have used mouse monoclonal ERG antibodies along with the other commercially available ERG antibodies, a rabbit anti-ERG monoclonal antibody clone EPR 3864 (Cat No. 2805-1) [26] and clone EPR 3863 (Cat No. 2849-1) obtained from Epitomics, Burlingame, CA and FLI-1 antibodies from Dr. Denis Watson, University of South Carolina, Charleston, SC. Anti-GAPDH (sc-25778, Santa Cruz Biotechnology, Santa Cruz, CA) sheep anti-mouse IgG-HRP (NXA931, GE Health Care, Buckinghamshire, UK) donkey anti-rabbit IgG-HRP (NA934, GE Health Care, Buckinghamshire, UK)

**Western blot assays.** Cells (Jurkat, MCF7, KG1, Molt4, VCaP, LNCaP) were lysed in Mammalian Protein Extraction Reagent (M-PER) (Pierce, Rockford, IL) containing protease inhibitor cocktail and phosphatase inhibitor cocktails I & II (Sigma, St Louis,

MO). Cell lysates equivalent to 50 µg of protein were separated on 4-12% Bis-Tris Gel (Invitrogen, Carlsbad, CA) and transferred to PVDF membrane (Invitrogen, Carlsbad, CA). Membranes were incubated with primary antibodies: Anti-ERG mouse monoclonal antibody (ERG MAb)[24] (1:500 dilution), rabbit monoclonal ERG (EPR 3864 and EPR 3863) antibodies (1:500 dilution) anti-GAPDH (sc-25778, Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for overnight. Membranes were washed three times for 5 minutes each at room temperature followed by treatment with secondary antibodies: sheep anti-mouse IgG-HRP or donkey anti-rabbit IgG-HRP at 24°C for 1 hour. Finally membranes were washed three times and bands were visualized with ECL Western blot detection reagent (GE Health Care, Buckinghamshire, UK).

**Immunofluorescence staining for ERG in cell lines and flow cytometry analysis.** The cancer cell lines used in this study were obtained from ATCC. VCaP cells were grown in DMEM/10%FCS+Penicillin/Streptomycin/L-Glutamine. LNCaP, T2, Jurkat, KG-1 and KG-1a cells were

cultured in RPMI/10%FCS/Penicillin/Streptomycin/L-Glutamine. On the day of the assay adherent cell lines (VCaP, LNCaP) were trypsinized to yield single cell suspensions while the non-adherent cells (T2, Jurkat, KG-1 and KG-1a) were utilized after a washing step. For each cell line, two aliquots of  $5 \times 10^5$  cells/tube were permeabilized with freshly prepared permeabilization buffer as directed by the manufacturer (eBioscience). One aliquot was stained with an IgG1 isotype control antibody (Invitrogen) and the second aliquot was stained with the anti-ERG antibody at a 1:20 dilution for 1 hour at 4°C. Then cells were washed and stained with FITC-conjugated rat anti-mouse IgG1 antibody (Clone A85-1, BD Pharmingen) for an additional 30 minutes at 4°C. Cells were then washed and analyzed by using a BD FACS Canto II flow cytometer. Data was collected on the total cell population and the analysis was performed by using FACS Diva software (version 5.03) (Becton Dickinson).

**Tissues and processing for Immunohistochemistry:** Fixation and impregnation FVB/N and C57BL6 mice embryos from various stages of development were dissected from pregnant females, washed in ice-cold phosphate-buffered saline (PBS) and fixed in ice-cold 4% paraformaldehyde overnight, sequentially dehydration, embedding, and sectioning steps were performed according to established protocols.

**Preparation for staining:** Slides (with 5-mm sections) were warmed at 60°C for 15 minutes and immediately immersed in xylene for effective removal of paraffin and processed additionally twice in xylene for 5 min each, washed twice in 100% ethanol for 5 min each, and subsequently rehydrated in 95, 75% ethanol, and PBS for 5 min at room temperature.

**Immunohistochemistry:** Antigen retrieval was performed on these slides in Antigen unmasking solution (Vector Biolabs, Burlingame, CA) by using vegetable steamer for 45 minutes and the slides were allowed to cool to room temperature for about 30 min. Slides were washed twice in 1xPBS and treated with 3% H<sub>2</sub>O<sub>2</sub> in ultrapure water for 15 minutes to quench the endogenous peroxidase activity. Immunodetection was performed using Mouse-to-mouse detection system kit according manufacturer's instructions (Millipore Inc. Billerica, MA). Briefly, nonspecific binding of the antibody was blocked by incubating the slides with pre-blocking solution for 10 minutes at RT, primary antibodies (200 pg/ml in 10% normal goat serum) at 4°C overnight or room temperature for 2 hours. Slides were washed twice in 1xPBS sites 5 min each, incubated with post-antibody blocking solution for 10 min. Slides were washed twice in 1xPBS

sites 5 min each and incubated with ready-to-use poly-HRP-Anti-Mouse/Rabbit IgG for 30 minutes, washed twice with 1xPBS for 5 minutes each. Color development was performed by using DAB as a substrate for peroxidase enzyme activity. The color reaction was stopped by washing/rinsing slides in tap water several times. Slides were counterstained with Hematoxyline for 2 minutes, rinsed in tap water for 5 mins, dehydrated sequentially in ascending concentration of alcohol, cleared in xylene and permanently mounted with Permount solution. The slides were scanned in Biomedical Instrumentation Center at Uniformed Services University of the Health Sciences using Olympus NanoZoomer Digital Pathology microscope at 40X magnification and digital images were taken from the scans.

## Acknowledgements

Authors wish to express sincere thanks to Dr David G. McLeod, Dr. David Burris and Dr. Norman Rich for their continued support throughout the work. The authors are grateful to Dr. Gyorgy Petrovics, CPDR/USU, Dr. Alfredo Molinolo, NIDCR/NIH for their valuable advices and comments during the progress of this study, Mr. Mohamed Mursal for technical assistance in FACS analysis. This work was supported by the CPDR Program HU0001-04C-1502 to David G. McLeod., NIH grant 1RO1 DK065977 to S.S and DoD grant PC073614 to T.S., A.D and S.S. The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or the U.S. Government.

## Conflict of Interest

The authors do not have any conflict of Interest.

## References

1. Aplan PD. Causes of oncogenic chromosomal translocation. *Trends Genet*, 2006. 22(1): 46-55.
2. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene*, 2007. 26(31): 4596-9.
3. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature*, 2007. 448(7153): 595-9.
4. Rao VN, Papas TS, and Reddy ES. *erg*, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. *Science*, 1987. 237(4815): 635-9.
5. Graves, BJ and Petersen JM. Specificity within the ets family of transcription factors. *Adv Cancer Res*, 1998. 75: 1-55.
6. Lee D, Park C, Lee H, et al. ER71 acts downstream of BMP, Notch, and Wnt signaling in blood and vessel progenitor specification. *Cell Stem Cell*, 2008. 2(5): 497-507.
7. Lelievre E, Lionneton F, Soncin F, and Vandembunder B. The Ets family contains transcriptional activators and repressors

- involved in angiogenesis. *Int J Biochem Cell Biol*, 2001. 33(4): 391-407.
8. Dhordain P, Dewitte F, Desbiens X, Stehelin D, and Dutertre-Coquillaud M. Mesodermal expression of the chicken erg gene associated with precartilaginous condensation and cartilage differentiation. *Mech Dev*, 1995. 50(1): 17-28.
  9. Ganan Y, Macias D, Dutertre-Coquillaud M, Ros MA, and Hurlé JM. Role of TGF beta s and BMPs as signals controlling the position of the digits and the areas of interdigital cell death in the developing chick limb autopod. *Development*, 1996. 122(8): 2349-57.
  10. Baltzinger M, Mager-Heckel AM, and Remy P. XI erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. *Dev Dyn*, 1999. 216(4-5): 420-33.
  11. Vlaeminck-Guillem V, Carrere S, Dewitte F, Stehelin D, Desbiens X, and Dutertre-Coquillaud M. The Ets family member Erg gene is expressed in mesodermal tissues and neural crests at fundamental steps during mouse embryogenesis. *Mech Dev*, 2000. 91(1-2): 331-5.
  12. Pham VN, Lawson ND, Mugford JW, et al. Combinatorial function of ETS transcription factors in the developing vasculature. *Dev Biol*, 2007. 303(2): 772-83.
  13. Schwachtgen JL, Janel N, Barek L, et al. Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene. *Oncogene*, 1997. 15(25): 3091-102.
  14. Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, and Huber P. Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. *J Biol Chem*, 1998. 273(12): 6750-5.
  15. Hasegawa Y, Abe M, Yamazaki T, et al. Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1. *Biochem Biophys Res Commun*, 2004. 316(1): 52-8.
  16. Pimanda JE, Chan WY, Donaldson IJ, Bowen M, Green AR, and Gottgens B. Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer. *Blood*, 2006. 107(12): 4737-45.
  17. Loughran SJ, Kruse EA, Hacking DF, et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. *Nat Immunol*, 2008. 9(7): 810-9.
  18. Kruse EA, Loughran SJ, Baldwin TM, et al. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. *Proc Natl Acad Sci U S A*, 2009. 106(33): 13814-9.
  19. Jaffredo T, Nottingham W, Liddiard K, Bollerot K, Pouget C, and de Bruijn M. From hemangioblast to hematopoietic stem cell: an endothelial connection? *Exp Hematol*, 2005. 33(9): 1029-40.
  20. Nikolova-Krsteovski V, Yuan L, Le Bras A, et al. ERG is required for the differentiation of embryonic stem cells along the endothelial lineage. *BMC Dev Biol*, 2009. 9: 72.
  21. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. *Blood*, 2008. 111(7): 3498-506.
  22. Anderson MK, Hernandez-Hoyos G, Diamond RA, and Rothenberg EV. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. *Development*, 1999. 126(14): 3131-48.
  23. Rivera RR, Stuver MH, Steenbergen R, and Murre C. Ets proteins: new factors that regulate immunoglobulin heavy-chain gene expression. *Mol Cell Biol*, 1993. 13(11): 7163-9.
  24. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. *Prostate Cancer Prostatic Dis*, 2010. 13(3): 228-37.
  25. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. *Proc Natl Acad Sci U S A*, 2008. 105(6): 2105-10.
  26. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. *Neoplasia*, 2010. 12(7): 590-8.
  27. Rothenberg EV, Telfer JC, and Anderson MK. Transcriptional regulation of lymphocyte lineage commitment. *Bioessays*, 1999. 21(9): 726-42.
  28. Rothenberg EV. Stepwise specification of lymphocyte developmental lineages. *Curr Opin Genet Dev*, 2000. 10(4): 370-9.
  29. Melet F, Motro B, Rossi DJ, Zhang L, and Bernstein A. Generation of a novel Fli-1 protein by gene targeting leads to a defect in thymus development and a delay in Friend virus-induced erythroleukemia. *Mol Cell Biol*, 1996. 16(6): 2708-18.